Published by Josh White on 1st February 2021
(Sharecast News) - Biotherapeutics developer Avacta Group announced on Monday that its joint venture with Daewoong Pharmaceutical, AffyXell Therapeutics, has closed a series A venture capital investment of $7.3m (£5.32m) to further develop its pipeline of next generation cell and gene therapies.